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Abstract. Clinical features of pregnancy in multidrug-resistant tuberculosis and type I diabetes mellitus 
comorbidities (a case report). Raznatovska O.M., Fedorec A.V., Shalmina M.O., Grekova T.A. Objective – to 
update the literature data with the clinical features of pregnancy in multidrug-resistant tuberculosis (MRD-TB) and 
type 1 diabetes mellitus (T1DM) comorbidities based on an example from own clinical experience. A clinical case of 
pregnancy course in MRD-TB and T1DM comorbidities was described based on our own clinical experience. We report 
the clinical case of newly diagnosed MRD-TB in a 38-year-old woman suffering from T1DM. Her general condition 
was unstable from satisfactory to moderately severe despite an adequate treatment of MRD-TB and T1DM with 
manifestations of intoxication syndrome and nephropathy. Adenomyosis with periodic bloody vaginal discharge was 
diagnosed. There was no clinical-radiological dynamics and sputum culture conversion. After an intensive phase of 
antimycobacterial therapy within 3 months, the patient got pregnant. Based on the medical indications (MRD-TB, 
absence of sputum culture conversion and clinical-radiological dynamics, moderate severity of T1DM, nephropathy) 
and adenomyosis with bloody vaginal discharge, the patient was requested to induce the pregnancy termination, and 
she consented. On month 7 of antimycobacterial therapy, an extensive drug-resistance of Mycobacterium tuberculosis 
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to antimycobacterial agents and negative dynamics by follow-up chest X-ray were diagnosed. The feature of pregnancy 
course in MRD-TB and T1DM comorbidities was an unfavorable coexistence of both these diseases simultaneously 
resulting in an induced abortion. In this case, doctors to working with patients suffering from both MRD-TB and 
T1DM are recommended to advise patients the use of contraception in order to prevent pregnancy during 
treatment of active MRD-TB. 
 
Реферат. Особливості перебігу вагітності при одночасному захворюванні на мультирезистентний 
туберкульоз і цукровий діабет 1-го типу (клінічний випадок). Разнатовська O.M., Федорець А.В., 
Шальміна M.O., Грекова TA. Мета дослідження – доповнення літературних джерел даними про особливості 
перебігу вагітності при одночасному захворюванні на мультирезистентний туберкульоз (МРТБ) і цукровий 
діабет (ЦД) 1-го типу на прикладі власного спостереження. Описано клінічний випадок власного спосте-
реження перебігу вагітності при одночасному захворюванні на МРТБ і ЦД 1-го типу. У представленому 
клінічному випадку пацієнтка 38 років, хвора на ЦД 1-го типу, захворіла на вперше діагностований МРТБ. На 
тлі адекватного лікування МРТБ та ЦД 1-го типу в пацієнтки загальний стан постійно коливався від 
задовільного до середньотяжкого з проявами інтоксикаційного синдрому та появою нефропатії, діагно-
стовано ендометріоз тіла матки з періодичними кров’янистими виділеннями, визначалися відсутність клініч-
но-рентгенологічної динаміки та конверсії мокротиння. Через 3 місяці інтенсивної фази антимікобак-
теріальної терапії пацієнтка завагітніла. Враховуючи медичні показання (МРТБ, відсутність конверсії 
мокротиння і клінічно-рентгенологічної динаміки, ЦД 1-го типу середньої тяжкості, нефропатія) та ендо-
метріоз тіла матки з кров’янистими виділеннями, пацієнтці було запропоновано зробити штучне переривання 
вагітності, на що вона погодилася. На тлі негативної динаміки в пацієнтки на 7-му місяці антиміко-
бактеріальної терапії була діагностована розширена резистентність мікобактерій туберкульозу до 
антимікобактеріальних препаратів. Особливостями перебігу вагітності при одночасному захворюванні на 
МРТБ і ЦД 1-го типу був несприятливий фон, спричинений цими двома захворюваннями. Наслідком цього стало 
штучне переривання вагітності. Рекомендаціями в цьому випадку є робота лікарів з пацієнтками, хворими 
одночасно на МРТБ і ЦД 1-го типу, у напрямку використання контрацепції з метою запобігання вагітності на 
період лікування активного МРТБ. 
 
To date, pulmonary multidrug-resistant tubercu-
losis (MRD-TB) remains one of the top causes of 
death among chronic communicable diseases [8] and 
diabetes mellitus (DM) – among chronic non-
communicable diseases [7]. 
Type 1 DM is characterized by a deficiency in 
insulin production, and people with this type of DM 
require lifelong administration of exogenous insulin 
[7] and optimal glycemic control [9]. It has been 
found that in the vast majority of pregnant women, 
DM is associated with an increased risk of both 
diabetic and obstetric complications [2] and this risk 
is doubled in the case of T1DM [3]. Poorly control-
led DM in pregnant women is related to dramatically 
adverse effect on both maternal and fetal health 
outcomes increasing the risk of fetal loss, stillbirth, 
perinatal and maternal mortality as well as 
developing birth defects which are the most common 
cause of perinatal mortality [7]. 
In T1DM pregnant women, the frequency of 
preterm labor is 60% [7]. There is strong evidence 
that T1DM pregnant women are at high risk for 
hypoglycemia occurring early in gestation which can 
cause intrauterine growth retardation [4]. At the same 
time, MRD-TB pregnant women also demonstrate a 
higher incidence of adverse treatment and childbirth 
outcomes as compared to pregnant women with 
sensitive causative agents of tuberculosis [1] together 
with serious maternal and fetal health risks [10]. 
All this is conducive to the growth of the number 
of patients with a combined course of these two 
diseases which mutually and adversely affect each 
other. It has long been known that tuberculosis com-
plications, a prolonged time of sputum culture 
conversion, high rate of treatment failure are DM-
associated [12]. Relatedly, tuberculosis activates a 
range of pathways associated with diabetic compli-
cations. A specific process leads to DM decompen-
sation due to worse glycemic control, causing glu-
cose intolerance [6]. Gadallah M. A. et al. [11] indi-
cate that the predictors of MRD-TB unsuccessful 
treatment are the delay in sputum culture conver-
sion, moderate or extensive lung affection and DM. 
Combined course of MRD-TB and T1DM beco-
mes especially unfavorable for pregnant women. 
Objective – to update the literature data with the 
clinical features of pregnancy in MRD-TB and 
T1DM comorbidities based on an example from own 
clinical experience. 
MATERIALS AND METHODS OF RESEARCH 
We report the clinical case of pregnancy course 
in MRD-TB and T1DM comorbidities based on our 
own clinical experience. A patient received inpatient 
treatment in the Department of Pulmonary Tuber-
culosis No 3 of the Clinical base of Phthisiology and 
Pulmonology Department of ZSMU at the Muni-
cipal Institution "Zaporizhzhia Regional Tubercu-
losis Clinical Dispensary" (ZRTBCD). 
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Clinical case presentation and discussion 
 
A 38-year-old woman G. was admitted to the 
ZRTBCD with newly diagnosed tuberculosis 
(NDTB), right lung infiltration. Destruction (+), 
Mycobacterium tuberculosis (MBT) +, microscopy 
(M) +, Category 1. T1DM, moderate severity. Anti-
mycobacterial therapy (AMBT) by category 1 was 
prescribed according to the Unified Clinical Protocol 
(UCP) "Tuberculosis" [5]. 
After being further examined with the help of 
molecular-genetic (MG) test, the patient presented 
MTB (+), MG (+), rifampicin (Rif) +. Based on the 
data obtained, the diagnosis was established: rifam-
picin resistant tuberculosis (RifTB), right lung infil-
tration. Destruction (+), MBT (+), M (+), MG (+), Rif 
(+), Category 4 (NDTB). T1DM, moderate severity. 
AMBT by category 4 was prescribed taking into 
account the drug sensitivity test (DST) data accor-
ding to the UCP "Tuberculosis" [5] and insulin therapy 
following the endocrinologist recommendations. 
After 2 weeks of inpatient treatment, she presen-
ted rise in body temperature up to 380C complaining 
of menstrual disorder and bloody vaginal discharge. 
Clinical blood analysis (CBA) was as follows: hemo-
globin (Hb) – 115 g/l; erythrocytes (Er) – 4.92 x 1012/l, 
leukocytes (L) – 12.0 x 109/l, erythrocyte sedimenta-
tion rate (ESR) – 36 mm/h, banded (b) – 12%, seg-
mented (s) – 75%, eosinophils (e) – 2%, lympho-
cytes (l) – 7%, monocytes (m) – 4%. 
The patient was consulted by a gynecologist. Her 
past gynecological history was unremarkable and 
she was not under medical check-up. Two preg-
nancy tests were negative. Transvaginal ultrasound 
was performed demonstrating echo signs of adeno-
myosis, heterogenous structure and thickness of the 
endometrium (hypoplasia?), small amount of free 




Based on these findings, the gynecologist estab-
lished the diagnosis: menstrual disorder, adeno-
myosis. An appropriate treatment was prescribed. 
After a month of inpatient treatment, the results 
of sputum culture in a liquid medium were obtained 
suggesting MBT resistance to first-line antimyco-
bacterial drugs (AMBD) – isoniazid (H), rifampicin 
(R) and pyrazinamide (Z). The patient was presented 
to MRD-TB expert panel and as a result the diagno-
sis was made: MRD-TB, right lung infiltration. Des-
truction (+), MBT (+), M (+), MG (+), Rif (+), 
Resistance І (HRZ), Category 4 (NDTB). T1DM, 
moderate severity. The appropriate therapy was 
administered again taking into account the results of 
DST according to the UCP "Tuberculosis" [5]. 
The patient was under regular follow-up of the 
endocrinologist. 
In the treatment course, her general condition 
was unstable from satisfactory to moderately severe 
with intoxication syndrome manifestations. The 
follow-up chest X-ray revealed no changes. There 
was no sputum culture conversion. From the third 
month of inpatient treatment, the patient demon-
strated an increase in serum creatinine level up to 
110.0 μmol/L (upper reference limit: 97 μmol/L) and 
urea level up to 9.1 mmol/L (upper reference limit: 
7.2 mmol/L). 
In this context, after the intensive phase of 
AMBT within 4 months, the patient complained of: 
menstrual disorder, bloody vaginal discharge and 
intoxication syndrome manifestations again. The 
follow-up consultation of gynecologist. The preg-
nancy test appeared to be positive. Transabdominal 
pelvic US showed echo signs of pregnancy, 4-
5 weeks of gestation. 
Based on the medical indications, the patient was 
requested to terminate pregnancy, and she con-
sented. The postoperative period was uneventful. 
The DST data obtained after the intensive phase 
of AMBT within 7 months were indicative of the 
extensive drug-resistance of MBT to AMBD: resis-
tance I (HRZ), resistance to second-line AMBD – 
ofloxacin (Ofx), kanamycin (Km) and capreomycin 
(Cm). The patient was prescribed the appropriate 
treatment regimen based on DST data according to 
the UCP "Tuberculosis" [5]. 
There was no sputum culture conversion throu-
ghout the entire intensive phase of AMBT (8 months). 
Radiological dynamics was weak positive with 
conglomerate mass lesions. The patient was repea-
tedly presented to surgical expert panel for elective 
surgery, but she categorically refused. 
RESULTS AND DISCUSSION 
Currently, there is consensus that neither active 
MRD-TB nor DM requires termination of pregnancy. 
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Safe treatment in usual management regimens du-
ring pregnancy seems possible but needs appropriate 
individual decision-making to eliminate the possible 
risks of adverse effects due to teratogenicity [7, 8]. 
In the presented clinical case, the 38-year-old 
woman suffering from T1DM diabetes developed 
newly diagnosed MRD-TB. Despite the adequate 
treatment of MRD-TB and T1DM, her general 
condition was unstable from satisfactory to mode-
rately severe with manifestations of intoxication 
syndrome and nephropathy. Adenomyosis with 
periodic bloody vaginal discharge was diagnosed. 
There was no clinical-radiological dynamics and 
sputum culture conversion. After the intensive phase 
of antimycobacterial therapy within 3 months, the 
patient got pregnant.  
In Ukraine, severe clinical forms of tuberculosis 
(progressive, chemoresistant or severely compli-
cated) and severe DM are among medical indica-
tions for pregnancy termination. Therefore, taking 
into account medical indications (MRD-TB, absence 
of sputum culture conversion and clinical-radio-
logical dynamics, moderate severity of T1DM, 
nephropathy) and adenomyosis with bloody vaginal 
discharge, the patient was requested to terminate 
pregnancy, and she consented. 
On month 7 of antimycobacterial therapy, an 
extensive drug-resistance of MBT to AMBD and 
negative dynamics by follow-up chest X-ray were 
diagnosed. 
CONCLUSIONS  
1. The feature of pregnancy course in MRD-TB 
and T1DM comorbidities was an unfavorable 
coexistence of both these diseases simultaneously 
resulting in an induced abortion.  
2. In this case, doctors to working with patients 
suffering from both MRD-TB and T1DM are 
recommended to advise patients the use of 
contraception in order to prevent pregnancy during 
treatment of active MRD-TB. 
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